Enveric Biosciences (ENVB) Short-term Investments (2016 - 2017)

Enveric Biosciences (ENVB) posted Short-term Investments of $82908.0 for Q3 2017, little changed sequentially from $82908.0 in Q2 2017.

Enveric Biosciences (ENVB) Short-term Investments (2016 - 2017) Analysis & Trends

Enveric Biosciences has reported Short-term Investments for 2 years, with the latest figure at $82908.0 in Q3 2017.

Quarterly Short-term Investments changed N/A year-over-year to $82908.0 in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $82908.0 (changed N/A YoY) and the FY2016 annual result came in at $82908.0, changed N/A from the prior year.
Short-term Investments was little changed at $82908.0 in Q3 2017 per ENVB's latest filing, from $82908.0 in the prior quarter.
Over five years, Short-term Investments peaked at $82908.0 in Q4 2016 and troughed at $82908.0 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Enveric Biosciences	5.66 Mn	-2.64 Mn	-

Download Data